| For: | Kayikcioglu E, Yüceer RO, Cetin B, Yüceer K, Karahan N. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma. World J Gastrointest Oncol 2023; 15(2): 343-351 [PMID: 36908327 DOI: 10.4251/wjgo.v15.i2.343] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i2/343.htm |
| Number | Citing Articles |
| 1 |
Izuma Nakayama, Changsong Qi, Yang Chen, Yoshiaki Nakamura, Lin Shen, Kohei Shitara. Claudin 18.2 as a novel therapeutic target. Nature Reviews Clinical Oncology 2024; 21(5) doi: 10.1038/s41571-024-00874-2
|
| 2 |
Xiaoping Zhou, Lanying Zou, Jun Xu, Huichuan Zhao. The ZIC2-Claudin-18.2 Axis Stimulates Pancreatic Cancer Progression and Metastasis via Activation of the ERK1/2 Signaling Pathway. The Tohoku Journal of Experimental Medicine 2025; 266(3) doi: 10.1620/tjem.2024.J114
|
| 3 |
Eugene Choi, Jinho Shin, Min-Hee Ryu, Hyung-Don Kim, Young Soo Park. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-68411-w
|
| 4 |
M. Fassan, I. Chau, H. Dasghaib, J. Hill, R. Pophale, K. Shitara. The prognostic role of Claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review. ESMO Gastrointestinal Oncology 2025; 9 doi: 10.1016/j.esmogo.2025.100210
|
| 5 |
Yuichiro Miki, Mami Yoshii, Ryoko Miyauchi, Tsubasa Bito, Kenji Kuroda, Hiroaki Kasashima, Tatsunari Fukuoka, Tatsuro Tamura, Masatsune Shibutani, Takahiro Toyokawa, Shigeru Lee, Masakazu Yashiro, Ayumi Shintani, Kiyoshi Maeda. Prognostic significance of Claudin18.2 expression in patients with gastric cancer. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-26388-0
|
| 6 |
Hongyan Yin, Rongkui Luo, Jing Lv, Wujian Mao, Hongcheng Shi. Relationship between [18F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer. European Radiology 2024; 35(6) doi: 10.1007/s00330-024-11186-5
|
| 7 |
Kelsey E. McHugh, Rish K. Pai, Robert C. Grant, Steven Gallinger, Jon Davison, Changqing Ma, Reetesh K. Pai. Claudin 18.2 Expression in 1404 Digestive Tract Adenocarcinomas Including 1175 Colorectal Carcinomas: Distinct Colorectal Carcinoma Subtypes Are Claudin 18.2 Positive. Modern Pathology 2025; 38(5) doi: 10.1016/j.modpat.2025.100712
|
| 8 |
E. Terán, R. Pazo, L. Caritá, M. Alsina, C. Hierro, C. Blanco, M. Reboredo, S. Landolfi, A. Zucchiatti, L. Visa, A. Calvo, A. López, R. Vidal-Tocino, C. Agra, I. Alés, S. Foti, B. García-Paredes, V. Genovesi, L. Fornaro, T. Sauri, I. Macías, E. Martínez, J. Martínez, C. Buges, P. Ribera, J.M. Herranz, D. Acosta, A. Vivancos, J. Tabernero, E. Élez, T.V. Tian, T. Macarulla. Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort. ESMO Open 2026; 11(2) doi: 10.1016/j.esmoop.2025.106053
|
| 9 |
Xiao-Yu Wang, De-Fan Yao, Gang Ren. Progress in research of tumor biomarkers and molecular imaging probes for gastric cancer. World Chinese Journal of Digestology 2024; 32(1) doi: 10.11569/wcjd.v32.i1.1
|
| 10 |
Katerina Zarampouka, Christos Tsiantas, Maria Athanasia Stavropoulou, Konstantinos Efthymiadis, Paschalis Theotokis, Sofia Gargani, Eleni Vrettou, Triantafyllia Koletsa, Maria Eleni Manthou, Soultana Meditskou. Correlation of CLDN18.2 and Tumor Microenvironment in Gastric Cancer: A Systematic Review. Cancers 2025; 17(13) doi: 10.3390/cancers17132120
|
| 11 |
Fangqian Du, Yuwei Xie, Shengze Wu, Mengling Ji, Bingzi Dong, Chengzhan Zhu. Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases. Journal of Hepatocellular Carcinoma 2024; doi: 10.2147/JHC.S483861
|
| 12 |
Su Ir Lyu, Caroline Fretter, Adrian Georg Simon, Sarah-Michele Spielmann, Alexander I. Damanakis, Yue Zhao, Christiane J. Bruns, Thomas Schmidt, Felix C. Popp, Dirk Waldschmidt, Alexander Quaas, Karl Knipper. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Translational Oncology 2024; 47 doi: 10.1016/j.tranon.2024.102044
|
| 13 |
Akira Matsuishi, Shotaro Nakajima, Motonobu Saito, Katsuharu Saito, Satoshi Fukai, Hideaki Tsumuraya, Ryo Kanoda, Tomohiro Kikuchi, Azuma Nirei, Akinao Kaneta, Hirokazu Okayama, Kosaku Mimura, Hiroyuki Hanayama, Wataru Sakamoto, Tomoyuki Momma, Zenichiro Saze, Koji Kono. The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-68970-y
|
| 14 |
Run Bao, Jing Qin, Rong Zhang, Zhuo Xu, Jiahao Liu, Jiaofeng Shen, Shunji Zhang, Yusong Zhang, Hong Zhu, Chunyan Huang, Yan Lu, Tianhua Liu, Wangyang Pu. Claudin 18.2 Expression and Outcomes of First-Line Chemoimmunotherapy in HER2-Negative Gastric or Gastroesophageal Junction Cancer: A Single-Center Retrospective Study. Current Oncology 2026; 33(8) doi: 10.3390/curroncol33080460
|
| 15 |
Bella L. Liu, James M. Cleary, Jay Shi, Jason L. Hornick, Lei Zhao. Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas. American Journal of Surgical Pathology 2025; 49(12) doi: 10.1097/PAS.0000000000002464
|
| 16 |
Aynur IŞIK, Güneş GÜNER, Can ZEYNELOĞLU, Seçil DEMİRKOL CANLI, Hakki TASTAN, Aytekin AKYOL. Claudin 18.2 Expression in Gastric Adenocarcinomas in a Large Turkish Cohort. Bolu Abant Izzet Baysal Universitesi Tip Fakultesi Abant Tip Dergisi 2023; 12(2) doi: 10.47493/abantmedj.1313791
|
| 17 |
Enver Akbas, Gözde Ülfer. Tissue Claudin 18.2 levels as a prognostic factor in gastric adenocarcinomas: A retrospective cohort study. Medicine 2026; 105(14) doi: 10.1097/MD.0000000000048192
|
| 18 |
Yang Wang, Geoffrey Chong. Immunotherapy in gastric adenocarcinoma – a rapidly evolving treatment landscape. Critical Reviews in Oncology/Hematology 2025; 216 doi: 10.1016/j.critrevonc.2025.104941
|
| 19 |
Maria Cecília Mathias-Machado, Victor Hugo Fonseca de Jesus, Alexandre Jácome, Mauro Daniel Donadio, Marcelo Porfirio Sunagua Aruquipa, João Fogacci, Renato Guerino Cunha, Leonard Medeiros da Silva, Renata D’Alpino Peixoto. Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?. Cancers 2024; 16(3) doi: 10.3390/cancers16030679
|
| 20 |
Yashwant Kumar Ratre, Nilabh Ghritlahre, Babita Pande, Tarun Sahu, Lakkakula Suhasini Sahithi, Shashikant Swarnkar, Henu Kumar Verma. Strategic integration of immunotherapy with chemotherapy, radiotherapy, and targeted therapy in gastric cancer management: A systematic review. World Journal of Gastroenterology 2026; 32(22): 115807 doi: 10.3748/wjg.v32.i22.115807
Abstract(68) |
Core Tip(72) |
Full Article(HTML)(308)
|
Full Article (PDF)-1259K(74)
|
Full Article with Cover (PDF)-1602K(38)
|
Full Article (XML)-294K(22)
|
Audio-278K(4)
|
Peer-Review Report-456K(31)
|
Answering Reviewers-225K(28)
|
Supplementary Material-369K(31)
|
Times Cited (0)
|
Total Visits (546)
|
Open
|
| 21 |
Jun Wu, Jinghua Lu, Qiuyue Chen, Haojie Chen, Yongqiang Zheng, Minggang Cheng. Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1494131
|
| 22 |
Yi Xie, Pengfei Guan, Dan Liu, Zhi Peng, Xiaotian Zhang, Lin Shen, Yang Chen. Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies. Journal of Hematology & Oncology 2026; 19(1) doi: 10.1186/s13045-026-01803-9
|
| 23 |
Francisco Cezar Aquino de Moraes, Luis Eduardo Rodrigues Sobreira, Maria Eduarda Cavalcanti Souza, Rommel Mario Rodríguez Burbano. The role of CLDN18.2 in gastric cancer prognosis: a systematic review and meta-analysis. Biomarkers 2024; 29(8) doi: 10.1080/1354750X.2024.2422965
|
| 24 |
Sung Hee Lim, Takeshi Kuwata, Minae An, Jung Yong Hong, Seung Tae Kim, Yuki Matsubara, Kohei Shitara, Jeeyun Lee. Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy. Journal for ImmunoTherapy of Cancer 2025; 13(9) doi: 10.1136/jitc-2025-012683
|
| 25 |
Hasan Çağrı Yıldırım, Fatih Yay, Gökhan Şahin, Fatih Kuş, Şuayib Yalçın. CPNE2 might serve as a new negative prognostic biomarker in gastric cancer. 3 Biotech 2025; 15(9) doi: 10.1007/s13205-025-04491-3
|